Granules India Ltd Q4 FY26 Earnings Analysis
Published 16 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹20.9K Cr
Price
₹858
Market Cap
₹20.9K Cr
P/E Ratio
32.2
Earnings Summary
Controlled substances and ADHD medications, including lisdexamfetamine, show strong growth potential with filings in multiple countries beyond the US (EU and ROW expected from FY '29 for finished doses, APIs earlier). Granules India aims for sustained PAT positive performance on an annual basis from FY '27, despite inherent quarter-to-quarter variations in the project-driven CDMO business.
📊 Revenue & Sales Performance
- →Controlled substances and ADHD medications, including lisdexamfetamine, show strong growth potential with filings in multiple countries beyond the US (EU and ROW expected from FY '29 for finished doses, APIs earlier).
- →Focus on complex product filings, especially in controlled substances and oncology, with first-to-file and NCE-1 targeted launches planned, supporting day-one market entry.
- →CDMO business, including peptides and chemicals (Ascelis), aims for sustainable profitability from FY '27, with active projects advancing to commercial supply.
- →Senn Chemicals identified as a key growth pillar, expected to contribute significantly over 3-4 years.
- →New API launches and integrated formulations continue to drive API segment growth.
- →Capex (~INR600 crores) will support broad-based expansion, including new API facility, IT, and US distribution center.
- →Working capital to sales targeted around 33% to support growth amid uncertain cost environment.
- →Overall, company anticipates steady volume and revenue growth driven by innovation, geographic expansion, and diversified project pipeline.
📈 Profitability & Margins
- →Granules India aims for sustained PAT positive performance on an annual basis from FY '27, despite inherent quarter-to-quarter variations in the project-driven CDMO business.
- →EBITDA margins are expected around 24-25% assuming gross margins hold at around 64-65%, though management remains cautiously optimistic due to cost pressures.
- →Peptide CDMO business (Ascelis Peptides/Senn Chemicals) is moving towards sustainable profitability starting FY '27 with positive EBITDA in Q4 FY '26.
- →Growth driven by complex generics, higher-value differentiated products, and new product launches as regulatory approvals progress.
- →Continued R&D investments (5.3% of sales) expected to support long-term differentiated growth.
- →Gross margin improved to 65% in FY '26; further margin expansion anticipated but subject to raw material/packing cost inflation and ability to secure price increases.
- →Net debt expected to be stable or slightly higher in FY '27 due to capex and working capital needs.
- →Market diversification and capacity expansion closely demand-linked to ensure profitable growth.
🏗️ Capital Expenditure Plans
- →Granules India is undertaking major capex investments including building peptide API capacity at Zurich and a brownfield manufacturing facility for intermediates in India.
- →Planning for a new India peptide API facility is underway, expected to commence approximately a year later.
- →A commercial DCDA plant in Vizag is planned with an estimated capex of around INR 200 crore, moving from pilot to commercial stage in 2 to 2.5 months.
- →FY '27 capex is expected to be broad-based (~INR 600 crore), including a new API facility, IT investments, and a U.S. distribution center/warehouse.
- →Capex funds raised via promoter and QIP funding will strengthen the balance sheet and support organic (capex, R&D, working capital) and inorganic growth opportunities.
- →Capex investments are demand-linked, aligned closely with customer commitments to avoid speculative capacity building.
💰 Fundraising & Capital Structure
- →No explicit mention of any immediate or planned new fundraising through debt or equity in the call.
- →Recent equity infusion of INR 6,656 million during FY '26 helped reduce net debt significantly.
- →Raised money from promoter and QIP a few months ago, utilized for strengthening balance sheet and funding organic/inorganic growth.
- →Organic investments include capex, working capital, R&D, while inorganic growth opportunities are being explored.
- →CFO Mukesh Surana mentioned potential small increase or flattish net debt for FY '27 depending on capex and working capital needs.
- →Overall, company appears focused on utilizing existing funds and balance sheet strength, with no announced plans for fresh fundraising at this time.
📋 Order Book & Pipeline
- →Specific details regarding the current order book for the Senn Chemicals CDMO project are not disclosed by the management.
- →Sanjay Kumar stated that they cannot share information related to the order book for the Senn project.
- →The CDMO capacity is demand-linked, with capex deployment based on customer program progress and commitments.
- →Utilization was healthy in Q4 FY'26, and new capacities coming online in the second half of the year are expected to be quickly utilized.
- →The customer base is diversified, avoiding high concentration on a few clients, thus minimizing dependency risks.
- →For other segments, no explicit pending orderbook numbers were given, but management emphasized ongoing projects and late-stage customer programs in the CDMO business.
Key Metrics
Frequently Asked Questions
What were Granules India Ltd Q4 FY26 results?
Controlled substances and ADHD medications, including lisdexamfetamine, show strong growth potential with filings in multiple countries beyond the US (EU and ROW expected from FY '29 for finished doses, APIs earlier). Granules India aims for sustained PAT positive performance on an annual basis from FY '27, despite inherent quarter-to-quarter variations in the project-driven CDMO business.
What is Granules India Ltd share price analysis?
Granules India Ltd currently shows a neutral. The stock trades at a P/E of 32.2 with a market cap of ₹20,941 Cr. Investors should review the full earnings analysis for detailed insights.
Is Granules India Ltd planning capital expenditure?
Granules India is undertaking major capex investments including building peptide API capacity at Zurich and a brownfield manufacturing facility for intermediates in India.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.